INOVIO to Present at Upcoming Scientific Conference
Rhea-AI Summary
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the upcoming Orphan Drug Summit in Boston, Massachusetts. The company will present on July 16 at 4:30 PM ET, focusing on their DMAb Technology and its transformational potential in rare disease treatment.
The presentation will explore the capabilities of next generation DNA medicine technology in addressing rare diseases, as part of a conference that brings together industry leaders and innovators to discuss technological and manufacturing advancements in the rare disease space.
Positive
- None.
Negative
- None.
Orphan Drug Summit
Date: July 16
Time: 4:30-4:55pm ET
Presentation: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302499023.html
SOURCE INOVIO Pharmaceuticals, Inc.